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Methimazole (MMI), an antithyroid drug, is associated with idiosyncratic toxicity. Reactive metabolites 
resulting from bioactivation of the drug have been implicated in these adverse drug reactions. Mimicry 
of enzymatic oxidation of MMI was carried out by electrochemically oxidizing MMI using a coulometric 
flow-through cell equipped with a porous graphite working electrode. The cell was coupled on-line to 
electrospray ionization mass spectrometry (EC/ESI-MS. ESI spectra were acquired in both negative and 
positive modes.  In acidic medium, ESI spectral analysis showed that the dimer was the main product,  
while in neutral and basic media,  methimazole sulfenic acid, methimazole sulfinic acid and methimazole 
sulfonic acid  were observed as the major electrochemical oxidation products. Oxidation of MMI and 
subsequent trapping with nucleophiles resulted in formation of adducts with N-acetylcysteine.   Some of 
the electrochemically generated species observed in these experiments were similar to metabolites that 
have been observed from in vitro and in vivo studies.   Trapping studies also showed that bioactivation 
of MMI proceeds predominantly through the S-oxide and not through formation of thyil radicals.  These 
results show that electrochemistry coupled to mass spectrometry can be used in mimicry of oxidative 
metabolism and subsequent high throughput screening of metabolites. 











































The conventional method of studying oxidative drug metabolism during preclinical experiments is 
through animal models (in vivo) or perfused organs in vitro.1 However, the use of animals in experiments 
involving scientific research and biological testing has raised concerns over the years among animal 
advocates.2 In view of this as well as the large number of drug candidates emerging and those existing, 
there has been a renewed interest in development of complementary tools for mimicry of oxidative 
metabolism. Although it remains a challenge to extrapolate data generated from such systems to actual 
In vivo systems, these biomimetic tools offer some advantages that are not inherent in conventional 
methods. Electrochemistry coupled on-line to liquid chromatograph/mass spectrometer (EC/LC/MS or 
EC/MS) has the potential to mimic redox metabolism.3-6 Members of the cytochromes P450 class 
(CYP450) of enzymes are responsible for the majority of phase I biotransformations leading to reactive 
electrophilic intermediates.7  The chemical reactivity of electrophilic metabolites usually prevents their 
detection in vivo since, by definition, they are short-lived and likely to undergo one or more structural 
modifications to form more stable final products.   Jurva and co-workers investigated the extent to 
which this technique could be used to mimic cytochrome P450 catalyzed reactions by comparing 
metabolites generated from EC/LC/MS to those that were generated from the P450 system. Their 
results showed that reactions such as N-dealkylation, S-oxidation, P-oxidation, alcohol oxidation and 
dehydrogenation that proceed via a mechanism initiated by one-electron oxidation or hydrogen 
abstraction  are amenable to electrochemical oxidation.8 
There are a number of therapeutic drugs based on simple sulfur chemistry. Our research in the past has 
focused on investigating the mechanism of S-oxidation of organosulfur compounds.9,10  Extensive studies 
from our laboratory have shown that nearly every organic sulfur compound presents a unique reactivity 
















bioactivation, resulting in formation of reactive and potentially  toxic metabolites from bioactivation of 
sulfur containing drugs.11  Many of the adverse reactions produced by penicillamine and other 
compounds with an active sulfhydryl group form a distinctive pattern when viewed as a class. 
Alterations in taste perception, mucocutaneous lesions, proteinuria due to immune-complex 
membranous glomerulopathy, and pemphigus are adverse reactions that have been encountered with 
all of these compounds.  Classic examples include the thiol, captopril, a still-used antihypertensive drug 
which comes with a black box warning and is associated with hepatotoxicity.12-14  It can only be used in 
low doses and after careful selection of patients to avoid idiosyncratic drug reactions and thus cannot be 
used for patients with severe hypertension.13  Troglitazone, a thiazolidinedione, developed for diabetes 
mellitus type 2, had to be withdrawn from the market because it caused severe liver injury.  Thiazoles 
such as Sudoxicam were withdrawn in Phase III trials when it was already apparent that the drug was 
rife with IDR’s while a closely-related drug, Meloxicam, has not been associated with any IDR’s.  
Methimazole, an antithyroid drug used in the treatment of hyperthyroidism, has been associated with 
idiosyncratic  toxicity, characterized by skin reactions, leucopenia, agranulocytosis, aplastic  anemia, 
hepatitis and cholestasis.15,16 The relationship between idiosyncratic adverse reactions and reactive 
metabolites is not well established.   There is  circumstantial evidence, however, that reactive 
metabolites are involved in the onset of idiosyncratic adverse reactions.17,18 We set out to investigate 
formation of any unexpected or reactive intermediates from MMI. The metabolites are electrophilic in 
nature, are reactive, and have the capacity to bind to nucleophilic cellular macromolecules which can 
then elicit an immune response.  EC/LC/MS method offers the advantage of generating and isolating 
reactive intermediates in cellular matrix free environments, since matrix components will immediately 
bind to the reactive metabolites resulting in evasion of detection.19-21 A range of metabolites have been 
suggested during oxidation of MMI. MMI metabolism is thought to occur through a P450-mediated 
















tandem of  sulfenic and sulfinic acids.22 However, some sources reported that FMO sequentially 
monooxygenates  intact methimazole to produce unstable  methimazole sulfenic  and sulfinic acids 
without ring scission.23  
The objective of this study was to use electrochemistry and mass-spectrometry to mimic oxidative 
metabolism in order to generate and characterize intermediates and  products using electrospray 
ionization.   Various electrochemical methods using modified electrodes to enhance catalytic oxidation 
of MMI have been developed and used for the determination of MMI at sub-micromolar  detection 
limits using cyclic voltammetry.24-26 While most of these studies were focusing on detection and 
determination of MMI using electrochemical techniques, our study is designed to explore metabolic fate 
of MMI. The  
 
Figure 1.Schematic of EC/ESI –MS system.  Coulochem III Electrochemical Detector  controls potential of 

















electrochemical oxidation of thiol  compounds such  MMI  is complicated by large anodic over potential 
and poor voltammetric signals. In the coulometric cell used in this study, the  eluent flows through the 
electrodes rather than by the electrodes as in convectional cells.  This maximizes the contact of the 
electro-active compound in solution with the electrode surface, ensuring that diffusion and convection 
controlled process do not  limit the electrochemical oxidation of the compound.27  
Experimental Section. 
Reagents: Reagent grade methimazole, reduced glutathione, N-acetylcysteine and  
methoxylamine were purchased from Sigma Aldrich (USA) and were used without further purification. 
Water solutions for electrochemical oxidation were purified using a Barnstead Sybron Corp. water 
purification unit capable of producing both distilled and deionized water (Nanopure ).  ICPMS, was used 
to evaluate concentrations of metal ions in the reagent water.  ICPMS results showed negligible 
amounts (< 0.1 ppb) of copper, iron and silver ions with approximately 1.5 ppb of cadmium and 0.43 ppb 
in lead as the highest metal ion concentrations.  In previous experiments from our lab, no discernible 
differences in kinetics data had been obtained between experiments run with chelators (EDTA, 
deferroxamine) and those run without, and so all experiments were carried out without the use of 
chelators.    Solvents used for electrochemical oxidation and mass spectrometry were HPLC grade. 
 
Instrumentation:   Electrochemical oxidations were performed using Thermo Scientific Dionex 5150  
Synthesis CellTM equipped with a flow through graphite  working electrode, solid state palladium 
reference electrode and a Palladium counter electrode (see Figure 1). The cell potential was controlled 
using Thermo Scientific Dionex Coulochem III electrochemical detector. The cell outlet was interfaced 
















the detector and cell; as well as shock, the synthesis cell and the detector were decoupled from the high 
voltage of the mass spectrometer using a high voltage decoupling union kit.  Samples were infused 
through a syringe pump at a flow rate of 10 µL/min for on-line experiments.  Mass spectra of the 
electrochemical oxidation products, were acquired on a high-resolution (m/Δm = 30 000) Thermo 
Scientific LTQ-Orbitrap Discovery mass spectrometer (San Jose, CA) equipped with an electrospray 
ionization source. The MS ESI source parameters were set as follows: spray voltage (kV), 2.5 in negative 
mode and 4.5 in positive mode; spray current (μA), 1.96; sheath gas flow rate, 20; auxiliary gas flow rate, 
0.01; capillary voltage (V), −16; capillary temperature (°C), 300; and tube lens (V), −115. Detection was 
carried out in both the negative ionization mode and positive (−ESI) for 4 min. The detection parameters 
were set up as follows: Analyzer; FTMS, positive and negative polarity; mass range; normal, resolution; 
30 000, scan type; centroid.    
On-line EC/ESI-MS electrochemical oxidation of methimazole. 
Experiments were carried out in acidic, neutral and alkaline medium.  100 µM MMI were dissolved in 
acidic medium which consisted of 20 % methanol with 80 % 20 mM formate buffer ( pH 2.75).  For 
neutral medium, a combination of 20 % methanol with 80 % 50 mM phosphate buffer (pH 7.4) was 
used.  Alkaline media utilized a 20 % methanol with 80% 20mM ammonium buffer solution (pH 10.2).  A 
500 µL sample was infused through the electrochemical cell at a flow rate of 10 µL/min before the cell 
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Table I legend: Those labeled with a prefix of ‘S’ indicate different forms of the substrate, methimazole, 
and those with ‘M’ indicate metabolites, either observed in this study or in previous studies. 
  
With the cell turned on, species generated from oxidation in each medium were monitored on the mass 
spectrum generated on-line. The potential was changed manually on the front panel of control module 
of ESA Coulochem III Electrochemical detector from 100 mv to 1200 mv. Each scan acquisition lasted for 
four minutes. The optimum potential was determined to be 600 mV vs Pd solid state reference.  Higher 
potentials resulted in a large number of unidentifiable fragments. 
Choice of supporting electrolyte and effect of pH 
 
Larger currents were attained in phosphate and in ammonium buffers. The same species obtained at pH 
7.4 in phosphate were also obtained in more alkaline media of pH 10.2.  Phosphate buffer, however, 
was not used for subsequent experiments.  This was because phosphate buffers are non-volatile and can 
clog the MS inlet capillary, and hence ammonium buffer was chosen as the suitable supporting 
electrolyte in subsequent experiments. In acidic medium the dimer was the predominant metabolite.  
 
 
Assessment of stability, reactivity of metabolites and off-line synthesis 
 
N-methylthiourea (M11) Methylthiourea  
sulfenic acid (M12) 
N-methylthiourea 


















In order to perform off-line synthesis of intermediates, stability of the electrochemically generated  was 
monitored over a period of 30 h. To collect samples off-line, samples were infused at 40 µL/min, with 
potential maintained at 600 mV. The samples were then collected in vials with one batch kept at room 
temperature and the other batch kept at -20 0C.  Samples were analyzed by ESI-MS.  Relative 
abundances of the intermediates at m/z 129 and 146 decreased significantly after 26 h. for both the 
samples that were kept frozen at  -20   C and those maintained at room temperature. There was a 75 % 
decrease in abundance of these intermediates  over this time duration.  In addition, stability of MMI was 
also monitored and was found to be stable for prolonged periods in solution.  
S-oxidation reactions in vitro had revealed that reactive intermediates are produced during oxidation of 
MMI and these can be eliminated by addition of nucleophiles such as glutathione to the reaction 
mixture22. In order to check reactivity of the intermediate species, samples were also incubated with a 
selected set of nucleophiles. Conjugates were observed when the samples were incubated with N-




















Figure 2.  On-line negative mode ESI-MS analysis of methimazole oxidized in ammonium buffer. MMI 
was infused at 10 µL/minute.  At this low flow rate the substrate has sufficient residence time in the 
oxidation cell allowing complete oxidation to sulfonic acid.  
 
Results. 
Technical limitations with respect to the spectrometer cavity could not allow for a faster flow rate than 
10 μL per minute.  Thus the residence time of the substrate in the oxidation chamber was generally long 
enough for full oxidation of MMI to its full oxidation products of the sulfonic acid at 600 mV.  The 
reaction could be slowed down by running the oxidation in basic environments.  Figure 2 shows the on-
line negative mode ESI spectrum obtained.  This spectrum shows a strong peak of the sulfonic acid at 
m/z =161.003 and another for the unoxidized substrate, MMI at m/z = 113.01.  In-between, there are 
MMIonline5acidic_140627172244 #65-77 RT: 1.05-1.25 AV: 13 NL: 2.55E6
T: FTMS - c ESI Full ms [110.00-300.00]



























































smaller peaks at m/z = 129.01 and 145.01.  These ramp to the sulfonic acid, m/z = 161.003 by jumps of 
16 amu’s signifying these are putative the sulfenic  (or S-oxide) and sulfinic acids (the dioxide).  The 
relative abundances of the peaks indicate that the sulfenic and sulfinic acid derivatives are relatively 
unstable.  The rate determining step for the oxidation of MMI is the formation of the S-oxide.   
 
         
 
      










Subsequent oxidation (after the first 2-electron oxidation) of the S-oxide is facile, hence the relative low 
abundance of these metabolites.  Structures of the S-oxide and sulfinic acid metabolites are shown in 
























Figure 4. Positive mode. On-line ESI spectrum acquired in basic medium.  This spectrum shows strong 
peaks for the dimer (m/z = 114.025, not labeled), the sulfenic acid, and the sulfonic acid.  The sulfinic 
acid is not observed under these conditions. 
 
Figure 4 shows spectra derived from on-line spectra in the positive mode.  As expected, the substrate 
now shows up at m/z = 115.03.  There is, surprisingly, a very strong peak for the S-oxide at 129.01.   
There is virtually no evidence for the sulfinic acid.  The major metabolite, before full oxidation to the 
sulfonic acid, is the dimer, at m/z = 114.025 (Figure 3c).  A slow oxidation rate will allow the electrophilic 
S-oxide to react with the thiol substrate in a condensation-type reaction to produce the dimer.  Dimeric 
disulfides are not as reactive as the original thiols, and thus they accumulate.  Their further oxidation 
rates back through the sulfenic acid are relatively slower. 
 
MMIonlinebasic200mv_140627172244 #3-10 RT: 0.02-0.10 AV: 8 NL: 1.35E6
T: FTMS + p ESI Full ms [110.00-300.00]













































































Figure 5. Negative mode.  Off-line synthesis and analysis of MMI oxidation products. The products were 
identified with a mass accuracy of 3.93 ppm and 3.43 ppm, absolute values, for the Methimazole sulfinic 
acid and Methimazole sulfonic acid respectively. 
 
Figure 5 shows the batch off-line experimental spectra.  Incubation period was long enough for the near-
full completion of the reaction.  Since this is a batch environment, with no outflow of unreacted 
metabolites, facile reactions were able to react to completion.  In contrast, negligible amounts of S-
oxide are observed; the major metabolite is the dioxide, methimazole sulfinic acid.  Since the batch 




MMI1100AMMONIA_140526174528 #11-15 RT: 0.15-0.18 AV: 5 NL: 6.03E6
T: FTMS - p ESI Full ms [100.00-1000.00]
































































Figure  6.  Off-line Positive mode. ESI spectrum showing the oxides of Methimazole.  Electrochemical 
oxidation can result in ionization of neutral molecules that are difficult to detect, resulting in only 
positively charged ions that can be detected in this mode.  
 
The positive mode results of the batch process are shown in Figure 6.  Basic environments destabilize 
electrophilic intermediates, and acidic environments stabilize them.  Thus, in Figure 6, the S-oxide is 



































































Electrospray Ionization results in acidic media. 
The Methimazole dimer was the predominant product in acidic medium (Figure 3c, structure M4).   
Figure 7 shows strong peaks for the singly charged dimer at m/z = 227.04 and the doubly charged 




Figure 7. Positive mode ESI in acidic medium. 
 
Experimental procedure for trapping experiment 
A 100 µM sample of MMI in 20 % methanol with 80% ammonium buffer, was infused through the 
electrochemical cell at a flow rate of 10uL/minute.  A solution of N acetyl cysteine, 100µM  from another 
MMI700AMMONIA #6-8 RT: 0.07-0.09 AV: 3 NL: 1.51E6
T: FTMS + c ESI Full ms [100.00-300.00]





























































syringe was then infused  at the same rate, the effluent from both channels combined and  mixed at a T-
junction flowing into the cavity of mass spectrometer as shown in Figure 1.  
 
Experimental results derived from trapping. 
Figure 8 shows the ESI spectrum derived from the use of N-acetylcysteine (NAC) as the trap.  One strong 
peak is observed, of a 1:1 adduct of NAC with MMI.  The experimental setup involved flowing NAC 
through a T-junction into the flow going into the spectrometer cavity (see Figure 1 schematic).  Thus 
NAC was not electrochemically oxidized.  It combined with the effluent from the electrochemical cell as 
a reducing thiol.  It reacts strongly with any electrophilic species from the electrochemical cell.  The 
absence of symmetric disulfides is important: it means no radicals are involved in this mechanism.  The 
only electrophile present in the electrochemical oxidation cell is the S-oxide. The decrease in abundance 
of metabolite and formation of the conjugate strongly indicates that it is the reactive metabolite. The 
sulfinic and sulfenic acids are not strong electrophiles.  Figure 8 thus shows that the sulfenic acid is very 
stable in the oxidizing environment but is quickly and quantitatively deactivated in a reducing 
environment such as in the presence of NAC.   This (a reducing environment) is the expected medium in 
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Figure 8 MMI   metabolite conjugate with  N-acetyl cysteine.  There is one dominant adduct 1:1 adduct 
of the N-acetylcysteine and MMI.  There is a small peak for the S-oxide and an even smaller peak for the 
dioxide. 
Mechanism. 
All the data derived from electrochemical oxidations suggests a very strong case for a viable S-oxide.   
This has been, previously, an elusive metabolite.    Very strong and stable peaks have been observed in 
Figures 4 and 6.  Figure 2, though not showing a strong sulfenic acid peak, does show a peak for the 
dimer.  This dimer is derived from a sulfenic acid (vide supra)  
The oxidation pathway has a direct correlation with the physiological effects of MMI.  The standard 
accepted oxidation pathway of sulfur-based drugs is through S-oxygenation, though the mechanism of 
this S-oxygenation differs with specific compounds based on the environment of the sulfur group.  All β-
amino sulfur compounds are oxidized in vivo and in vitro to as far as the sulfonic acid without cleavage 
of the C – S bond.  Thus most biologically active molecules such as cysteine, glutathione, and cysteamine 
















reaction was found to be strictly 1:3; with formation of the sulfonic acid with very little detectable 
sulfate by BaSO4 precipitation: 
 3Br2  +  RSH  +  3H2O   →   RSO3H  (Structure M3)  +  6H
+  +  6Br- 
Most deleterious effects of bioactive compounds are ascribed to the reactive metabolites produced 
during the first pass metabolism31.  By nature of the physiological environment, such reactive 
metabolites are never observed.  The first set of experiments carried out to detect possible reactive 
intermediates of MMI involved its reaction with aqueous bromine.  This is a ‘clean’ and strong oxidant 
that oxidizes in 2 one-electron steps to produce only Br- as its reduced product: 
  ½Br2 (aq) + e-     Br-  E
o/ V = 1.09 
  This affords the determination of the possible metabolites without interference from the oxidant.  A 
1:1 mixture of MMI and aqueous bromine imparts a 2-electron oxidation which should limit oxidation of 
MMI to the sulfenic acid.  If the sulfenic acid is stable enough, it should be observed in the ESI spectrum.  
Figure 9 shows a spectrum of a 1:1 mixture of MMI and aqueous bromine.  Even though the spectrum 
shows the sulfinic and sulfonic acids; the major metabolite is surprisingly, the S-oxide (Figure 3a, 
Structure M1).  In the absence of the reducing physiological environment, this highly unstable, 
electrophilic S-oxide can be stabilized.  Unstable S-oxides are known to disproportionate or to form 
thiosulfinates.  They are also expected to react with the nucleophilic remaining thiol to produce a dimer: 
  RSOH  +  RSH  →  RSSR  +  H2O   
Under insufficient oxidant equivalents, the substrate will partition into its most stable intermediates at 
those conditions.   Spectrum in Figure 9 shows that the sulfinic acid, as expected, is not as stable as the 
sulfonic acid, which is the final oxidation product.  This spectrum was taken after complete consumption 
of bromine and before full rearrangement of the sulfur compounds as evidenced by the coexistence of 
















pH of the reaction solution decreased due to formation of H+ according to the reaction stoichiometry.  
Thus the m/z peak at 116.99 can be ascribed to the substrate, and the 115.03 to the dimer.  After long 
incubation periods the substrate peak disappears completely, with a concomitant increase in the 
dimeric species and other unidentifiable thiosulfinates.  The sulfenic and sulfinic acids still show up at 
the expected m/z values because of their acidity, and thus unlikely to be further protonated despite the 


















Figure 9. ESI spectrum of oxidation of methimazole using bromine in a 1:1 mixture ratio. As expected, 
the sulfenic acid is the major metabolite in these conditions of excess reductant. 
 
Proposed  mechanism for electrochemical oxidation of methimazole 
Our experimental results can now allow us to produce a plausible mechanism of electrochemical 
oxidation of MMI.  This is shown in Scheme 1.  Electrochemical oxidation of sulfur-based drugs is 
complicated by the fact that sulfur centers generally oxidize via 2-electron jumps, while electrochemical 
abstractions generally involve a single electron transfer at a time.  Starting with the thiol center would 
produce a sulfur-based thiyl-type radical on abstraction of the first electron.  This would immediately 
precipitate a cascade of free radical reactions with a strong formation of the dimeric disulfide.  Our 
results thus lead us to the conclusion that the abstraction of the first electron results in the formation of 
MMBR13_140610205402 #9-24 RT: 0.09-0.21 AV: 16 NL: 7.93E6
T: FTMS + c ESI Full ms [50.00-200.00]




























































a positive charge delocalized mostly over the C-N-C network and not a sulfur-based radical.  Zwitterionic 







Comparison with biological metabolism. 
In general, the electrochemical species generated from electrochemical oxidation of MMI , shown here 
in this manuscript, are similar to metabolites obtained from  in vitro incubations with microsomes.  
















electrochemical process is a ‘cleaner’ oxidation environment than that afforded by microsomes.  Our 
electrochemical oxidation platform involves the most easily oxidizable part of the molecule without any 
regard to other parameters present in bimolecular activations such as stereochemistry.  Thus one would 
expect a compact set of metabolites, while microsomal oxidations would produce a broader spectrum of 
possible metabolites.  The major metabolites observed in microsomal oxidations have been echoed by 
our electrochemical system.  The maintenance of an oxidizing environment in the electrochemical 
environment has allowed for the observation of those highly electrophilic intermediates that would 
otherwise have been quenched by the reducing physiological environment.  Metabolism by microsomes 
involves primarily the flavin-containing monooxygenases (FMO’s) and the Cytochromes P450 group of 
enzymes.  FMO’s are a family of drug-metabolizing enzymes that use FAD, NADPH and molecular oxygen 
to catalyze the oxygenation of a large number of xenobiotics  containing ‘soft’ nucleophiles such as 
sulfur, phosphorus and nitrogen.33,34  These FMO’s convert xenobiotics into polar metabolites  by adding 
oxygen so that they can subsequently be easily eluted through the kidneys.35   While initially thought to 
be a single enzyme; FMO’s are now known to contain at least 11 isoforms, with 5 of them having been 
characterized to date.36,37  Since MMI is a well-tolerated drug for hyperthyroidism, its in vitro  and in vivo  
metabolism has been extensively studied.   Human, rat and pig microsomal incubations with MMI have 
concluded that the major activation of MMI is performed by FMO’s rather than CYP450’s.   Presence of 
FMO’s however, seemed to deactivate CYP-based bioactivations, and it has since been established that 
MMI is a competitive inhibitor of FMO’s.38,39  Isolation of the effect of CYP450’s can be determined by 
heating, which deactivates FMO’s or addition of N-octylamine, which inhibits FMO bioactivations.   The 
variety of metabolites obtained which involved ring cleavage to obtain methyl thiourea and its oxo-acids 
(structures  M11 – 13 in Table 1) can be attributed to CYP450-mediated bioactivations.   This can be 
justified through the initial epoxidation of MMI (structure M9) whose subsequent hydrolysis product of 
















wide variety of possible metabolism products when microsomal oxidations are utilized to metabolize 
MMI.  The major pathway of microsomal bioactivation of MMI involves S-oxygenation, with the sulfinic 
acid (structure M2) as the major metabolite.  While the sulfenic acid has been postulated (structure 
M1), microsomal incubations had never been able to isolate it; even though formation of M2 has to pass 
through M1.  Our study has been able to isolate this formerly postulated metabolite.  The deactivation 
of CYP450’s is clearly related to formation of a highly reactive electrophilic metabolite of MMI derived 
from FMO’s.  This has been observed with the oxidation of a novel kinase inhibitor, TG100435.40,41  Its 
bioactivation by FMO’s gives an S-oxygenated S-Oxide, TG100855, which not only deactivates Cyp450’s 
but is also reduced back to TG100435 during the deactivation. Thus the products, kinetics and dynamics 
of microsomal bioactivations are expected to be complex.  Our electrochemical oxidations simplify this 
process.  This makes evaluation of physiological effects, especially toxicities, easier to determine. 
Conclusion 
Bioactivations of sulfur-based drugs have always been difficult to determine. Sulfur chemistry is 
generally complex, characterized by free radical mechanisms and formation of polymeric species.  
Toxicities of sulfur-based drugs have been attributed to formation of highly reactive sulfur oxo-acids and 
depletion of glutathione by the formation of reactive metabolites.  The most-postulated metabolite, the 
sulfenic acid, had never been isolated until now, using electrochemistry on-line with electrospray 
ionization. 
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Electrochemistry-Coupled to Mass Spectrometry in Simulation of Oxidation of Methimazole: 
Identification and characterization of metabolites 
Research Highlights: 
This manuscript, although not the first of its type involving mimicry of metabolic activation of a long-
used drug, is the first one that involves Methimazole, a drug still in major use for hyperactive thyroid 
disorders and Graves Disease.  Using this electrochemical technique, we have been able to detect 
genotoxic metabolites that had been hitherto elusive.  We can use this technique to rationalize 
observed toxicities associated with this drug. 
